Tandem Diabetes Care, Inc.
Tandem Diabetes Care designs, develops, and commercializes technology solutions for people with diabetes. The companys flagship products are the t:slim X2 insulin delivery system and Tandem Mobi insulin pump. It also sells single-use products like cartridges and infusion sets. Additionally, the company offers software updates, a data management platform called Tandem Source, and a mobile app called Sugarmate.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- EV/EBIT (100.00) is significantly higher than the sector mean.
- The Price to Free Cash Flow ratio (169.71) is significantly higher than the sector mean.
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 162.8 |
| ROIC | 3.3% |
| Net Debt/EBITDA | 100.0 |